About IBEX Technologies (CVE:IBT)
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. The company produces a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. It also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, the company provides lyophilization services related to the making of components for disposable medical devices, which are used in the hemostasis point of care market. IBEX Technologies Inc. offers its enzymes to manufacturers of medical devices, quality control labs, and academic research institutions. The company is based in Montreal, Canada.
Industry, Sector and Symbol
Trailing P/E Ratio2.33333333333333
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity0.11%
Return on Assets0.08%
IBEX Technologies (CVE:IBT) Frequently Asked Questions
What is IBEX Technologies' stock symbol?
IBEX Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IBT."
When will IBEX Technologies make its next earnings announcement?
Who are some of IBEX Technologies' key competitors?
Some companies that are related to IBEX Technologies include Redx Pharma (REDX), LiDCO Group (LID), Akers Biosciences (AKR), Evgen Pharma (EVG), Proteome Sciences (PRM), Immune Pharmaceuticals (IMNP), Shield Therapeutics (STX), ImmunoCellular Therapeutics (IMUC), Sorrento Tech (ROKA), Great Basin Scientific (GBSN), Baxano Surgical (BAXSQ), Savient Pharmaceuticals (SVNTQ), Sphere Medical (SPHR), NephroGenex (NRXGQ), Air Methods (AIRM), Alexza Pharmaceuticals (ALXA), Allos Therapeutics (ALTH) and Ambit Biosciences (AMBI).
Who are IBEX Technologies' key executives?
IBEX Technologies' management team includes the folowing people:
- Paul Baehr, Chairman of the Board, President, Chief Executive Officer (Age 69)
- Richard Collin, Director - Finance, Secretary
- Robert J. DeLuccia, Lead Independent Director (Age 70)
- Bruce Connop Ph.D., Director (Age 44)
- Joseph Zimmermann Ph.D., Director
- Thomas O. Hecht M.D., Independent Director (Age 64)
- Danilo Netto, Independent Director
How do I buy IBEX Technologies stock?
Shares of IBEX Technologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IBEX Technologies' stock price today?
One share of IBEX Technologies stock can currently be purchased for approximately C$0.28.
How big of a company is IBEX Technologies?
IBEX Technologies has a market capitalization of C$6.92 million.
How can I contact IBEX Technologies?
IBEX Technologies' mailing address is 5485 Pare St Suite 100, MONT-ROYAL, QC H4P 1P7, Canada. The company can be reached via phone at +1-514-3444004.
MarketBeat Community Rating for IBEX Technologies (IBT)MarketBeat's community ratings are surveys of what our community members think about IBEX Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
IBEX Technologies (CVE:IBT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
IBEX Technologies (CVE:IBT) Earnings History and Estimates Chart
IBEX Technologies (CVE IBT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/19/2018|| || || || || || || || |
|11/20/2017||Q4 2017||C$0.09||C$1.46 million||View||N/A|
|3/20/2017||Q2 2017||C$0.01||C$1.54 million||View||N/A|
|12/16/2016||Q1 2017||C$0.01||C$1.21 million||View||N/A|
|6/21/2016||Q3 2016||C($0.02)||C$0.70 million||View||N/A|
|3/17/2016||Q2 2016||C$0.01||C$1.14 million||View||N/A|
|12/17/2015||Q1 2016||C$0.01||C$1.42 million||View||N/A|
|11/5/2015||Q4 2015||C$0.04||C$1.25 million||View||N/A|
|6/18/2015||Q3 2015||C($0.01)||C$0.89 million||View||N/A|
|3/20/2015||Q2 2015||C($0.01)||C$0.72 million||View||N/A|
|12/17/2014||Q1 2015||C($0.01)||C$0.63 million||View||N/A|
|10/29/2014||Q4 2014||C($0.01)||C$1.00 million||View||N/A|
|6/25/2014||Q3 2014||C$0.01||C$1.14 million||View||N/A|
|12/19/2013||Q1 2014||C($0.02)||C$0.88 million||View||N/A|
|11/29/2013||Q4 2013||C$0.02||C$1.20 million||View||N/A|
|3/14/2013||Q2 2013||C($0.02)||C$0.74 million||View||N/A|
IBEX Technologies (CVE:IBT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for IBEX Technologies (CVE:IBT)
No dividend announcements for this company have been tracked by MarketBeat.com
IBEX Technologies (CVE IBT) Insider Trading and Institutional Ownership History
IBEX Technologies (CVE IBT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
IBEX Technologies (CVE IBT) News Headlines
IBEX Technologies (CVE:IBT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
IBEX Technologies (CVE IBT) Stock Chart for Thursday, February, 22, 2018